Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Combination Therapy in Patients With Coronavirus Disease 2019 and Primary Antibody Deficiency.
J Infect Dis
; 225(5): 820-824, 2022 03 02.
Article
in English
| MEDLINE | ID: covidwho-1722476
ABSTRACT
BACKGROUND:
Previous reports highlighted the efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific monoclonal antibodies (mAbs) against coronavirus disease 2019.METHODS:
We conducted a prospective study on the clinical outcome and antiviral effects of mAbs added to standard of care therapy in SARS-CoV-2-infected patients with primary antibody defects.RESULTS:
Median time of SARS-CoV-2 quantitative polymerase chain reaction (qPCR) positivity was shorter in 8 patients treated with mAbs (22 days) than in 10 patients treated with standard of care therapy only (37 days, P=.026). Median time of SARS-CoV-2 qPCR positivity from mAb administration was 10 days.CONCLUSIONS:
The SARS-CoV-2 mAbs treatment was effective and well tolerated in patients with primary antibody defects.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Common Variable Immunodeficiency
/
Primary Immunodeficiency Diseases
/
SARS-CoV-2
/
COVID-19 Drug Treatment
/
Antibodies, Viral
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
J Infect Dis
Year:
2022
Document Type:
Article
Affiliation country:
Infdis
Similar
MEDLINE
...
LILACS
LIS